Lmm buys $98,336,102 stake in Intrexon Corp (XON)

Intrexon Corp (XON) : Lmm scooped up 2,950 additional shares in Intrexon Corp during the most recent quarter end , the firm said in a disclosure report filed with the SEC on Nov 14, 2016. The investment management firm now holds a total of 3,074,925 shares of Intrexon Corp which is valued at $98,336,102.Intrexon Corp makes up approximately 5.57% of Lmm’s portfolio.

Other Hedge Funds, Including , Vanguard Group Inc boosted its stake in XON in the latest quarter, The investment management firm added 175,550 additional shares and now holds a total of 3,943,657 shares of Intrexon Corp which is valued at $126,118,151. Intrexon Corp makes up approx 0.01% of Vanguard Group Inc’s portfolio.Pacer Advisors boosted its stake in XON in the latest quarter, The investment management firm added 689 additional shares and now holds a total of 5,480 shares of Intrexon Corp which is valued at $161,222. Intrexon Corp makes up approx 0.02% of Pacer Advisors’s portfolio. Concert Wealth Management sold out all of its stake in XON during the most recent quarter. The investment firm sold 9,081 shares of XON which is valued $235,561. First Quadrant L Pca sold out all of its stake in XON during the most recent quarter. The investment firm sold 16 shares of XON which is valued $422.

Intrexon Corp closed down -0.23 points or -0.73% at $31.19 with 11,41,018 shares getting traded on Monday. Post opening the session at $31.35, the shares hit an intraday low of $30.97 and an intraday high of $31.85 and the price fluctuated in this range throughout the day.Shares ended Monday session in Red.

On the company’s financial health, Intrexon Corp reported $-0.24 EPS for the quarter, missing the analyst consensus estimate by $ -0.07 based on the information available during the earnings call on Nov 9, 2016. Analyst had a consensus of $-0.17. The company had revenue of $48.99 million for the quarter, compared to analysts expectations of $51.70 million. The company’s revenue was down -8.2 % compared to the same quarter last year.During the same quarter in the previous year, the company posted $-0.34 EPS.

Intrexon Corporation is engaged in the field of synthetic biology. The Company designs builds and regulates gene programs which are Deoxyribonucleic Acid (DNA) sequences that consist of genetic components. The Company’s synthetic biology capabilities include the ability to control the amount location and modification of biological molecules to control the function and output of living cells. The Company’s technologies include UltraVector RheoSwitch Therapeutic System Cell Systems Informatics Protein Engineering AttSite Recombinases LEAP (Laser Enabled Analysis and Processing) Antibody Discovery Neurospora & Agaricus Platforms Endometrial Regenerative Cells ActoBiotics Porcine Research Models and BeyondBio. The Company serves various markets including health food energy environment and consumer. The Company has five operating divisions: Human Therapeutics Synthetic Immunology Animal Sciences Agricultural Biotech and Industrial Products.

Leave a Reply

Intrexon Corp - Is it time to Sell?

Top Brokerage Firms are advising their investors on Intrexon Corp. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.